期刊文献+

左旋多巴微囊胃内漂浮片犬体内药物动力学研究 被引量:4

Pharmacokinetic study of Levodopa Microcapsules Intragastric Floating Tablets in Beagle dogs
下载PDF
导出
摘要 目的:建立左旋多巴微囊胃内漂浮片在比格犬体内的血药质量浓度的测定方法,并对其体内药动学行为进行研究。方法建立HPLC法测定血样中左旋多巴的质量浓度,流动相为水-甲醇(95∶5),其中水相含EDTA 0.08 mmol · L^ -1、磷酸二氢钾70 mmol · L^ -1、庚烷磺酸钠2.08 mmol · L^-1,流速为0.5 mL · min^-1,荧光检测,激发波长278 nm ,发射波长325 nm。6只Bea-g le犬分别给予复方左旋多巴微囊胃内漂浮片,并在给药后多点前肢静脉采血。用该方法检测血浆中左旋多巴的质量浓度,用3P97计算药动学参数。结果该方法的线性范围为0.078~20μg · mL^ -1,最低定量限为0.078μg · mL^ -1,日内RSD<8.10%,日间RSD<13.52%,回收率为105.1%~113.9%。左旋多巴微囊胃内漂浮片在犬体内的药时曲线符合单室模型,主要药物动力学参数分别为 t1/2(1.09±0.46)h,tmax(1.32±0.54)h,Cmax(1.33±0.31)μg· mL^-1;AUC为(3.31±1.26)μg·h·mL^ -1。结论该方法简单、快速,可用于比格犬的左旋多巴血药质量浓度的测定和药动学研究。 Objective To explore the plasma concentration measurement method and to study the pharmacokinetic profiles of Levo-dopa Microcapsules Intragastric Floating Tablets in Beagle dogs .Methods An HPLC method was developed to determine the con-tent of levodopa in the blood samples from Beagle dogs .The mobile phase was consisted of water and methanol(95∶5) ,containing EDTA 0 .08 mmol · L^ -1 ,potassium dihydrogen phosphate 70 mmol · L^ -1 ,and heptane sulfonate 2 .08 mmol · L^ -1 .The flow rate of mobile phase was 0 .5 mL · min^-1 .The excitation wavelength of fluorescence detection was 278 nm ,and the emission wave-length of fluorescence detection was 325 nm .Six Beagle dogs were given Levodopa Microcapsules Intragastric Floating Tablets ,and the blood from the forelimb vein were collected at different time after administration .According to the result of concentration of levodopa in plasma ,pharmacokinetic parameters were calculated with 3P97 software .Results The linear range was 0 .078-20μg · mL -1 .The minimum detection limit was 0 .078 μg · mL -1 .The RSD of within-day was below 8 .10% ,and the RSD of be-tween-days was below 13 .52% .The recovery was between 105 .1%-113 .9% .The concentration-time curve of Levodopa Microcap-sules Intragastric Floating Tablets fitted to one-compartment model .The main pharmacokinetic parameters of Levodopa Microcap-sules Intragastric Floating Tablets was t1/2 (1 .09 ± 0 .46) h ,tmax (1 .32 ± 0 .54) h ,Cmax (1 .33 ± 0 .31)μg · mL^ -1 ,and AUC (3 .31 ± 1.26)μg · h · mL ^-1 .Conclusion The method was simple and rapid ,which can be used to determine the levodopa plasma con-centration and study the pharmacokinetic profiles .
出处 《西北药学杂志》 CAS 2014年第2期173-177,共5页 Northwest Pharmaceutical Journal
基金 新疆维吾尔自治区高新技术研究发展计划(编号:201110106) 乌鲁木齐市科学技术计划项目(编号:G121320003)
关键词 左旋多巴微囊胃内漂浮片 高效液相色谱法 药物动力学 Levodopa Microcapsules Intragastric Floating Tablets HPLC pharmacokinetics
  • 相关文献

参考文献14

二级参考文献55

  • 1徐刚锋,张文玉.应用卡波姆971PNF制备胃内漂浮型缓释片及其体外评价[J].中国药科大学学报,2003,34(4):317-321. 被引量:15
  • 2卢耀茹,张钧寿,杨敏,梁淼.多潘立酮胃内滞留型缓释片的制备[J].中国药科大学学报,2003,34(4):327-329. 被引量:13
  • 3丁燕飞,姚瑶,陶昱斐,郭俐麟.均匀设计法优化硫酸特布他林微囊的处方[J].中南药学,2006,4(1):10-12. 被引量:1
  • 4于民,张扬达.左旋多巴治疗并发症的研究进展及治疗对策[J].国外医学(神经病学.神经外科学分册),1996,23(5):233-236. 被引量:2
  • 5Nutt JG.On-off phenomenon:relation to levodopa pharmacokinetics and pharmacodynamics[J].Ann Neurol,1987,22:535-540.
  • 6Tolokan A,Klebovich I,Balogh-Nemes K,et al.Automated determination of levodopa and carbidopa in plasma by high-performance liquid chromatography-electrochemical detection using an on-line flow injection analysis sample pretreatment unit[J].J Chromatogr B Biomed Sci Appl,1997,698(1-2):201-207.
  • 7Schimiet RF,Thew G.Human physiology,springer-verlay,Berlin Heiderg[Z].New York,1983,681.Albert J S. Physiopathology of the cardiovascular system.Little Brown and company Boston/Toronto.
  • 8Yeh KC,August TF,et al.Pharmacokinetics and bioavailability of Sinemet CR:A summary of human studies[J].Neurology 39(Suppl 2),1989,11:25-37.
  • 9[1]Metman LV,Hoff J,Mouradian MM,et al.Fluctuations in plasma le vodopa a nd motor responses with liquid and tablet levodopa/carbidopa[J].Mov Disord ,1994,9(4)∶463-465.
  • 10[2]Hyland K,Clayton PT.Aromatic L-amino acid decarboxylase deficiency:diagn ostic methodology[J].Clin Chem,1992,38(12)∶2405-2410.

共引文献109

同被引文献44

  • 1中国药典[S].二部.2010.
  • 2Paul HG,Jason MM,Robert CH, et al. Parkinson's disease among American Indians and Alaska natives: a nation- wide prevalence study [J]. Mov Disord, 2012,27 ( 11 ) : 1456- 1459.
  • 3Navailles S,Lagiere M ,Contini A,et al. Multisite intrae- erebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinso- nian brain [J]. ACS Chem Neurosci ,2013,4(5) :680-692.
  • 4Lipski J, Nistico R, Berretta N, et al. L-DOPA : a scape- goat for accelerated neurodegeneration in Parkinson's dis- ease [J]. Prog Neurobiol, 2011,94 (4) : 389-407.
  • 5Di Stefano A, Sozio P, Cerasa LS, et al. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment [J]. Curr Pharm Des,2011,17(32):3482-3493.
  • 6Goole F,Vanderbist K,Amighi. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms [J]. International Journal of Pharmaceutics, 2007, (334) :35-41.
  • 7Goole PH,Deleuze F,Vanderbist,et al. New levodopa sus- tained-release floating minitablets coated with insoluble acrylic polymer [J]. European Journal of Pharmaceutics and Biopharmaceutics ,2008, (68) :310-318.
  • 8Ren TY,Yang XX,Wu N ,et al. Sustained-release formu- lation of levodopa methyl esterPoenserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats [J]. Neuroscience Letters, 2011, (502 ) : 117 - 122.
  • 9Paul HG,Jason MM,Robert CH,et al. Parkinson's disease a-mong American Indians and Alaska natives : a nationwideprevalence study[j]. Mov Disord,2012 ,27(11) : 1456-1459.
  • 10Navailles S,Lagiere M, Contini A,et al. Multisite intracere-bral microdialysis to study the mechanism of L-DOPA induceddopamine and serotonin release in the parkinsonian brain [J].ACS Chem Neurosci, 2013 ,4(5) : 680-692.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部